COVID-19 therapeutics

被引：8

作者：

Focosi, Daniele ^{[1
]}

Franchini, Massimo ^{[2
]}

Maggi, Fabrizio ^{[3
]}

Shoham, Shmuel ^{[4
]}

机构：

[1] Pisa Univ Hosp, North Western Tuscany Blood Bank, Pisa, Italy

[2] Carlo Poma Hosp, Div Hematol & Transfus Med, Mantua, Italy

[3] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Rome, Italy

[4] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA

来源：

CLINICAL MICROBIOLOGY REVIEWS | 2024年 / 37卷 / 02期

关键词：

COVID-19; SARS-CoV-2; antiviral therapies; small-molecule antivirals; monoclonal antibodies; convalescent plasma; CONVALESCENT PLASMA THERAPY; LETHAL MUTAGENESIS; SARS-COV-2; MOLNUPIRAVIR; REMDESIVIR; METABOLITE; PLACEBO; MULTICENTER; OUTPATIENTS; IVERMECTIN;

D O I：

10.1128/cmr.00119-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches to choose from, but efficacy of those approaches often remains controversial or compromised by viral evolution. Uncertainties still persist regarding the best therapies for high-risk patients, and the drug pipeline is suffering fatigue and shortage of funding. In this article, we review the antiviral activity, mechanism of action, pharmacokinetics, and safety of COVID-19 antiviral therapies. Additionally, we summarize the evidence from randomized controlled trials on efficacy and safety of the various COVID-19 antivirals and discuss unmet needs which should be addressed.

引用

页数：34

共 50 条

[31] The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Naidoo, Dhaneshree Bestinee
Chuturgoon, Anil Amichund
MOLECULAR DIAGNOSIS & THERAPY, 2023, 27 (02) : 193 - 226
[32] COVID-19 Therapeutics for Nonhospitalized Older Adults
Patel, Pragna
Wentworth, David E.
Daskalakis, Demetre
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (18): : 1511 - 1512
[33] The Potential of Antiviral Peptides as COVID-19 Therapeutics
Mahendran, Arun Suria Karnan
Lim, Yin Sze
Fang, Chee-Mun
Loh, Hwei-San
Le, Cheng Foh
FRONTIERS IN PHARMACOLOGY, 2020, 11
[34] COVID-19: Clinical aspects and therapeutics responses
Khan, Suliman
Ali, Ashaq
Shi, Hongwei
Siddique, Rabeea
Shabana
Nabi, Ghulam
Hu, Junjie
Wang, Tiejun
Dong, Men
Zaman, Wajid
Han, Guang
SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (08) : 1004 - 1008
[35] The potential role of nanomedicine on COVID-19 therapeutics
Mainardes, Rubiana Mara
Diedrich, Camila
THERAPEUTIC DELIVERY, 2020, 11 (07) : 411 - 414
[36] A review of COVID-19 therapeutics in pregnancy and lactation
Jorgensen, Sarah C. J.
Tabbara, Najla
Burry, Lisa
OBSTETRIC MEDICINE, 2022, 15 (04) : 225 - 232
[37] Role of microRNAs in COVID-19 with implications for therapeutics
Arghiani, Nahid
Nissan, Tracy
Matin, Maryam M.
BIOMEDICINE & PHARMACOTHERAPY, 2021, 144
[38] COVID-19: potential therapeutics for pediatric patients
Younis, Nour K.
Zareef, Rana O.
Fakhri, Ghina
Bitar, Fadi
Eid, Ali H.
Arabi, Mariam
PHARMACOLOGICAL REPORTS, 2021, 73 (06) : 1520 - 1538
[39] Complement Factors in COVID-19 Therapeutics and Vaccines
Kurtovic, Liriye
Beeson, James G.
TRENDS IN IMMUNOLOGY, 2021, 42 (02) : 94 - 103
[40] Tracking a Vaccine and Developing Therapeutics for COVID-19
Gould, Kathleen Ahern
DIMENSIONS OF CRITICAL CARE NURSING, 2020, 39 (06) : 293 - 297

← 1 2 3 4 5 →